The impact of bisphosphonate therapy on survival of lung cancer patients with bone metastasis

Pneumon

Volumn 22, Issue 1, 2009, Pages 25-37

  Zarogoulidis, Konstantinos ^a   Boutsikou, Efimia ^a   Zarogoulidou, Vasiliki ^a   Lithoxopoulou, Hellie ^a   Tsiouda, Theodora ^a   Ballasoulis, Georgios ^a   Kontakiotis, Theodoros ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Bisphosphonates; Bone metastasis; Chemotherapy; Non small cell lung cancer; Zoledronic acid

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOPLATIN; CREATININE; DOCETAXEL; ETOPOSIDE; IFOSFAMIDE; MESNA; VITAMIN D; ZOLEDRONIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; BONE SCINTISCANNING; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE COURSE; DRUG WITHDRAWAL; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HUMAN; JAW OSTEONECROSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SIDE EFFECT; SINGLE DRUG DOSE;

EID: 77953384363     PISSN: 1105848X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. BMC Cancer. 2007; 7:8. Published online 2007 January 12. doi: 10.1186/ 1471-2407-7-8.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80:1588-1594.
3. Bloomfield DJ. Should bisphosphonates be part of the standard therapy of patients with multiple myeloma or bone metastases from other cancers? An evidence-based review. J Clin Oncol 1998; 16:1218-1225.
4. Seraflni AN. Therapy of metastatic bone pain. J Nucl Med 2001; 42:895-906.
5. Kohno N. Zoledronic Acid Significantly Reduces Skeletal Complications Compared With Placebo in Japanese Women With Bone Metastases From Breast Cancer: A Randomized, Placebo-Controlled. Trial J Clin Oncol 2005; 23 (15):3314-3321.
6. Rosen LS, Gordon D, Kaminski M et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98 (8):1735-44.
7. Fleisch H. Development of bisphosphonates. Breast Cancer Research 2000; 4:30-34.
8. Goffinet M, Thoulouzan M, Pradines A et al. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006; 6-60.
9. Iguchi T, Miyakawa Y, Yamamoto K et al. Nitrogen-containing bisphosphonates induce S-phase cell cycle arrest and apoptosis of myeloma cells by activating MAPK pathway and inhibiting mevalone pathway. Cell Signal 2003; 15:719.
10. Denoyelle C, Hong L, Vannier JP et al. New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects. Br J Cancer 2003; 88:1631.
11. Oades GM, Senaratne SG, Clarke IA et al. Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells. J Urol 2003; 170:246.
12. Senaratne SG, Mansi JL, Colston KW. The bisphosphonate zoledronic acid impairs Ras membrane [correction of impairs membrane] localization and induces cytochrome c release in breast cancer cells. Br J Cancer 2002; 86:1479.
13. Yamada J, Tsumo NH, Kitayama J et al. Anti- Angiogenic Property of Zoledronic Acid by Inhibition of Endothelial Progenitor Cell Differention. J. Surg. Research. Article in press (2008).
14. Demers LM, Costa L, Chinchilli VM, Gaydos L, Curley E, Lipton A. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995; 41:1489-94.
15. Brown JE, Cook RJ, Major P et al. Bone Turnover Markers as Predictors of Skeletal Complicationsin Prostate Cancer, Lung Cancer, and Other Solid Tumors. Journal of the National Cancer Institute 2005; 97(1):59-69.
16. Lipton A, Cook R, Saad F et al. Normalization of bone markers is associated with improved survival in patients with bone metastases form solid tumors and elevated bone resorption receiving zoledronic acid. Cancer 2008; 113():193-201.
17. Costa L, Demers LM, Gouveia-Oliveira A, Schaller J, Costa EB, de Moura MC et al. Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status. J Clin Oncol 2002; 20:850-6.
18. Demers LM, Costa L, Lipton A. Biochemical markers and skeletal metastases. Cancer 2000; 88(suppl): 919-26.
19. Vinholes JJ, Purohit OP, Abbey ME, Eastell R, Coleman RE. Relationships between biochemical and symptomatic response in a double-blind randomised trial of pamidronate for metastatic bone disease. Ann Oncol 1097; 8:1243-50.
20. http://www.zometa.com/around-the-world/ european-product-characteristics.jsp
21. Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Annals of Oncology 2008; (3):420-32.
22. Berenson J & Hirschberg R. Safety and convenience of a 15-minute infusion of zoledronic acid. The Oncologist 2004; 9:319-329.
23. Bone Pain Inventory. Ann Acad Med Singapore 1994; 23:129-138.
24. Ibrahim T, Barbanti F, Giorgio-Marrano G et al. Osteonecrosis of the jaw in patients with bone metastases treated with bosphosphonates: A retrospective study.The Oncologist 2008; 13:330-336.
25. Jagdev SP, Coleman RE, Shipman CM et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer 2001; 84:1126-1134.
26. Neville-Webbe HL, Evans CA, Coleman RE, Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol 2006; 27:92-103.
27. Vogt U, Bielawski KP, Bosse U, Schlotter CM. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/ metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/ paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep 2004; 12:1109-1114.
28. Mystakidou K, Katsouda E, Parpa E et al. Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline. Med Oncol 2005; 22:195-201.
29. Lu S, Zhang J, Zhou Z et al. Synergistic inhibitory activity of zoledronate and paclitaxel on bone metastasis in nude mice. Oncol Rep. 20008; 20(3):581-7.
30. Hirsh V, Major PP, Lipton A et al. Zoledronic Acid and Survival in Patients with Metastatic Bone Disease form Lung Cancer and Elevated Markers of Osteoclast Activity. J Thorac Oncol 2008; 3(3):228-236.
31. Rosen LS, Gordon D, Tchekmedyian NS et al. Long term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in pts with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004; 100(12):2613-2621.
32. Lipton A. The safety of zoledronic acid. Expert Opin Drug Saf 2007; 6(3):305-313.
33. Bertelli G, Heouaine A, Arena G et al. Weekly docetaxel and zoledronic acid every 4 weeks in hormne-refractory prostate cancer patients. Cancer Chemother Pharmacol 2006; 57(1):46-51.
34. Vordos D, Paule B, Vacherot F et al. Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer BJU Int 2004,94(4):524-527.
35. Efstathiou E, Bozas G, Kostakopoulos A et al. Combination of docetaxel, estramustine phosphate and zoledronic acid in androgen-independent metastatic prostate cancer: efficacy, safety and clinical benefit assessment. Urology 2005;65(1):126-130.
36. Kopec IC & Groeger JS. Life-threatening fluid and electrolyte abnormalities associated with cancer. Crit Care Clin 1998; 4(1): 81-105.
37. Sehbai SA, Azim Mirza M, Ericson GS et al. Osteonecrosis of the Jaw associated with biphosphonate therapy: tips for the practicing oncologist. http://www.CommunityOncology.net 2007, 4(1):w1-w9.
38. Saab F, Gleason DM, Murray R et al. Long term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004, 96 (11):879-882.
39. Guarneri V, Donati S, Nicolini M, Giovanelli S. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 years. Oncologist 2005; 10(10):842-848.
40. Ali SM, Esteva FJ, Hortobagyi G et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19(14): 3434-3437.